Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab

Publication date: Available online 26 February 2018
Source:Annals of Allergy, Asthma & Immunology
Author(s): Merin Kuruvilla
Hypereosinophilic syndrome (HES) is a rare disease defined by organ damage directly attributable to hypereosinophilia that is either primary (neoplastic), secondary (reactive) or idiopathic. The mainstay of therapy in idiopathic HES centers around systemic steroids, and cytoreduction with hydroxyurea and interferon-alfa in steroid refractory cases. We describe the successful treatment of recalcitrant, idiopathic cutaneous HES with reslizumab, a humanized interleukin-5 blocker.



http://ift.tt/2EV10P9